10 Jan 2024 – Novogene further expands its long-read sequencing capacity with the acquisition of six additional PacBio Revio sequencers, augmenting its fleet of multi-platforms sequencing technology. This strategic investment underline Novogene’s commitment to enhancing its long read sequencing capacity and global presence.

Novogene aims to strengthen its service offerings in long-read sequencing applications with PacBio latest Revio sequencer. As an early adopter of PacBio Revio, Novogene is at the forefront of long-read sequencing, impacting various research areas. The Revio sequencer provides a 15-fold increase in data output, significantly expediting research in human health, disease, and complex genomic studies, offering swift, complete, and highly accurate long-read data. The company’s significant investment ensures the broader application of this technology in key areas such as rare diseases, drug development, cancer research, neurological disorders and population health. As long-read sequencing becomes more cost-effective and efficient, its application in disease diagnosis and various other fields is expected to see sustained growth.

“We stand as a global leader among sequencing service providers, distinguished by our diverse range of platforms, extensive production capacity, and deep R&D expertise. Our commitment is to be a cornerstone in the life sciences industry, offering solutions that are not only accurate and rapidly delivered but also of superior quality and cost-effective” said Li Yixue, General Manager of Novogene Global Product Center.

“We are thrilled to further collaborate with Novogene, a critical partner for PacBio since 2017. Throughout the years, Novogene has promoted our technologies and applications and will continue to do so in the future. We look forward to our continued collaboration going forward” said Jeff Eidel, Chief Commercial Officer at PacBio.

Over the last six months, Novogene has achieved remarkable progress in utilizing the PacBio Revio system for its services. The platform has effectively utilized over 1000 SMRT Cells and extended its service to encompass a wide array of more than 300 species including mammals, aquatic life, mollusks, insects, agricultural produce, and medicinal plants. The platform achieved a record single-cell output of 121.36G while maintaining a consistent 7-day turnaround time. Novogene’s commitment to third-generation genomics research, bolstered by high-quality PacBio HiFi data, has enabled significant advancements from chromosome-level to T2T assembly, enhancing genomic research capabilities. To date, Novogene has constructed genome maps for over 1000 species and contributed to 137 co-authored publications in international journals, amassing an impressive cumulative impact factor of over 1,400.

Looking ahead to 2024, Novogene is set to continue leveraging a variety of advanced technology platforms to cater to the varied needs of its customers. The company commits to ensuring the stability and extensive reach of its global services while staying customer-focused. By providing cost-effective, high-quality, and dependable products and services, Novogene aims to solidify its position as a trusted research partner worldwide.

About Novogene

Novogene is a pioneer in applying cutting-edge molecular biology technology and high-performance computing to research in the fields of life science and human health. Our vision is to continue as a global leader in the delivery of genomics services and solutions. With one of the largest sequencing capacities in the world, we utilise our deep scientific knowledge, first-class customer service and unsurpassed data quality to help clients realise their research goals in the rapidly evolving world of genomics. Novogene is committed to become your trusted genomics partner.